Cystic Fibrosis Lung Disease in Adult Patients

References

• Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry. 2005. Annual Data Report for the Center Directors. Bethesda, MD.
   Google Scholar
• Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child. 1938; 56: 344–399.
   Google Scholar
• Farber S. Pancreatic function and disease in early life v. pathological changes associated with pancreatic insufficiency in early life. Arch Pathol. 1944; 37: 238–250.
   Google Scholar
• di Sant'Agnese PA. Fibrocystic disease of the pancreas, a generalized disease of exocrine glands. JAMA. 1956; 160: 846–853.
   Google Scholar
• Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest. 2004; 125(suppl 1): 1S–39S.
   PubMed Web of Science ®Google Scholar
• Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007(10); 176: 957–969.
   PubMed Web of Science ®Google Scholar
• Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: Chromosome walking and jumping. Science. 1989; 245(4922): 1059–1065.
   PubMed Web of Science ®Google Scholar
• Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: Cloning and characterization of complimentary DNA. Science. 1989; 245(4925): 1066–1073.
   PubMed Web of Science ®Google Scholar
• Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A. Identification of the cystic fibrosis gene: Genetic Analysis. Science. 1989(4922);245: 1073–1080.
   PubMed Web of Science ®Google Scholar
• Pilewski JM, Frizzell RA. Role of CFTR in airway disease. Physiol Rev. 1999; 79: (suppl 1): S215–S255.
   Google Scholar
• Rowe SM, Miller S, Sorscher EJ. Cystic Fibrosis. N Engl J Med. 2005; 352(19): 1992–2001.
   Google Scholar
• Gibson RL, Bums JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003; 168(8): 918–951.
   PubMed Web of Science ®Google Scholar
• Ratjen F, Döring G. Cystic Fibrosis. Lancet. 2003(9358);361: 681–689.
   PubMed Web of Science ®Google Scholar
• KcKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest. 2006; 130(5): 1441–1447.
   Google Scholar
• Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med. 2006; 173(5): 475–482.
   PubMed Web of Science ®Google Scholar
• Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med. 1996; 335(3): 179–188.
   PubMed Web of Science ®Google Scholar
• Widerman E, Miltner L, Sexauer W, Fiel S. Health status and sociode-mographic characteristics of adults receiving a cystic fibrosis diagnosis after age 18 years. Chest. 2000; 118(2): 427–433.
   Web of Science ®Google Scholar
• Wilschanski M, Dupuis A, Ellis L, Jarvi K, Zielenski J, Tullis E. Mutations in the cystic fibrosis transmembrane gene and in vivo transepithelial potentials. Am J Respir Crit Care Med. 2006; 174(7): 787–794.
   PubMed Web of Science ®Google Scholar
• Gan KH, Geus WP, Bakker W, Lamers CB, Heijerman HG. Genetic and clinical features of patients with cystic fibrosis diagnosed after the age of 16 years. Thorax. 1995; 50(12): 1301–1304.
   PubMed Web of Science ®Google Scholar
• Rodman DM, Polis JM, Heltshe SL, et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med. 2005(16); 171: 621–626.
   Google Scholar
• Gilljam M, Ellis L, Corey M, Zielenski J, Dune P, Tullis DE. Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood. Chest. 2004; 126(4): 1215–1224.
   Google Scholar
• Mickle JE, Cutting GR. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations. Clin Chest Med. 1998; 19(3): 443–458.
   PubMed Web of Science ®Google Scholar
• Schluchter MD, Konstan MW, Drumm ML, Yankaskas JR, Knowles MR. Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. Am J Respir Crit Care Med. 2006; 174(7): 780–786.
   PubMed Web of Science ®Google Scholar
• Drumm ML, Konstan MW, Schluchter MD, et al; Gene Modifier Study Group. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med. 2005; 353(14): 1443–1453.
   PubMed Web of Science ®Google Scholar
• Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest. 2002; 109(5): 571–577.
   PubMed Web of Science ®Google Scholar
• Randell SC, Boucher RC; University of North Carolina Virtual Lung Group. Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol. 2006; 35(1): 20–28.
   PubMed Web of Science ®Google Scholar
• Widdicombe JH. Regulation of the depth and composition of airway surface liquid. J Anal. 2002; 201 (4): 313–318.
   Google Scholar
• Travis SM, Singh PK, Welsh MJ. Antimicrobial peptides and proteins in the innate defense of the airway surface. Curr Opin Immunol. 2001; 13(1): 89–95.
   Google Scholar
• Cole AM, Liao HI, Stuchlik O, Tilan J, Pohl J, Ganz, T. Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol. 2002; 169(12): 6985–6991.
   PubMed Web of Science ®Google Scholar
• Rogan MP, Geraghty P, Greene CM, O'Neill SJ, Taggart CC, McElvaney NG. Antimicrobial proteins and polypeptides in pulmonary innate defense. Respir Research. 2006; 7: 29–40.
   PubMed Web of Science ®Google Scholar
• Moraes TJ, Plumb J, Martin R, et al. Abnormalities in the pulmonary innate immune system in cystic fibrosis. Am J Respir Crit Care Med. 2006; 34(3): 364–374.
   Google Scholar
• Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human ß-Defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell. 1997; 88(4): 553–560.
   PubMed Web of Science ®Google Scholar
• Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell. 1996; 85(2): 229–236.
   PubMed Web of Science ®Google Scholar
• Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections in cystic fibrosis. J Clin Invest. 2002; 109(3): 317–325.
   PubMed Web of Science ®Google Scholar
• De Kievit TR, Iglewski BH. Bacterial quorum sensing in pathogenic relationships. Infect Immun. 2000; 68(9): 4839–4849.
   Google Scholar
• Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med. 2005; 171(11): 1209–1223.
   PubMed Web of Science ®Google Scholar
• Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 2004; 42(5): 1915–1922.
   PubMed Web of Science ®Google Scholar
• Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev. 2002; 15(2): 194–222.
   PubMed Web of Science ®Google Scholar
• Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulm. 1992; 12(3): 158–161.
   PubMed Web of Science ®Google Scholar
• Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol. 1995; 48(8): 1041–1049.
   Google Scholar
• Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA. 2005; 293(5): 581–588.
   PubMed Web of Science ®Google Scholar
• Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med. 1995; 151(4): 1075–1082.
   PubMed Web of Science ®Google Scholar
• Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med. 1994; 150(2): 448–454.
   PubMed Web of Science ®Google Scholar
• Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic Fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis. 1990; 141(4Pt 1): 914–921.
   Google Scholar
• Berger M. Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good? Clin Rev Allergy. 1991; 9(1–2): 119–142.
   Google Scholar
• Vender RL. Therapeutic potential of neutrophil-elastase inhibition in pulmonary disease. J Investig Med. 1996; 44(9): 531–539.
   Google Scholar
• Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of highdose ibuprofen in patients with cystic fibrosis. N Engl J Med. 195;332(13): 848–854.
   Google Scholar
• Conway SP, Morton AM, Oldroyd B, et al. Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors. Thorax. 2000; 55(9): 798–804.
   Google Scholar
• Stephenson A, Jamal S, Dowdell T, Pearce D, Corey M, Tullis E. Prevalence of vertebral fractures in adults with cystic fibrosis and their relationship to bone mineral density. Chest. 2006; 130(2): 539–544.
   Google Scholar
• Aris RM, Merkel PA, Bachrach LK, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metabol. 2005; 90(3): 1888–1896.
   Google Scholar
• Lanng S, Thoisteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr. 1994; 83(8): 849–853.
   PubMed Web of Science ®Google Scholar
• Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration. 2006; 73(1): 27–33.
   PubMed Web of Science ®Google Scholar
• Flume PA, Strange C, Ye X, Ebeling M, Hulsey T, Clark LL. Pneumothorax in cystic fibrosis. Chest. 2005; 128(2): 720–728.
   PubMed Web of Science ®Google Scholar
• Flume PA, Yankaskas JR, Ebeling M, Hulsey T, Clark LL. Massive hemoptysis in cystic fibrosis. Chest. 2005; 128(2): 729–738.
   PubMed Web of Science ®Google Scholar
• Kraemer R, Rudeberg A, Hadorn B, Rossi E. Relative underweight in cystic fibrosis and its prognostic value. Acta Paediatr Scand. 1978; 67(1): 33–37.
   PubMed Web of Science ®Google Scholar
• Huang NN, Schidlow DV, Szatrowski TH, et al. Clinical features, survival rate, and prognostic factors in young adults with cystic fibrosis. Am J Med. 1987; 82(5): 871–879.
   Google Scholar
• Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol. 1988; 41 (6): 583–591.
   PubMed Web of Science ®Google Scholar
• Moran A, Hardin D, Rodman D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract. 1999; 45(1): 61–73.
   PubMedGoogle Scholar
• Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med. 2000; 162(3 Pt 1): 891–895.
   PubMed Web of Science ®Google Scholar
• Olivier KN, Weber DJ, Wallace RJ, et al; Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care. Med. 2003; 167(6): 810–812.
   Google Scholar
• Coenye T, Vandamme P, Govan JR, LiPuma JJ. Taxonomy and identification of Burkholderia cepacia complex. J Clin Microbiol. 2001; 39(10): 3427–3436.
   PubMed Web of Science ®Google Scholar
• Tablan OC, Chorba TL, Schidlow DV, et al. Pseudomonas cepacia colonization in patients with cystic fibrosis: Risk factors and clinical outcome. J Pediatr. 1985; 107(3): 382–387.
   PubMed Web of Science ®Google Scholar
• Jones AM, Dodd ME, Govan JR, et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax. 2004; 59(11): 948–951.
   PubMed Web of Science ®Google Scholar
• De Boeck K, Malfroot A, Van Schil L, et al; Belgian Burkholderia cepacia Study Group. Epidemiology of Burkholderia cepacia complex colonization in cystic fibrosis patients. Eur Respir J. 2004; 23(6): 851–856.
   Google Scholar
• Frangolias DD, Mahenthiralingam E, Rae S, et al. Burkholderia cepacia in cystic fibrosis; Variable disease course. Am J Respir Crit Care Med. 1999; 160(5 Pt 1): 1572–1577.
   Google Scholar
• Manno G, Dalmastri C, Tabacchioni S, et al. Epidemilogy and clinical course of Burkhoklderia cepacia complex infections, particularly those caused by different Burkhoklderia cenocepacia strains, among patients attending an Italian cystic fibrosis center. J Clin Microbiol. 2004; 42(4): 1491–1497.
   Google Scholar
• Saiman L, Siegel J. Infection Control in cystic fibrosis. Clin Microbio Rev. 2004; 17(1): 57–71.
   PubMed Web of Science ®Google Scholar
• Ravilly S, Robinson W, Suresh S, Wohl ME, Berde CB. Chronic pain in cystic fibrosis Pediatrics. 1996; 98(4 Pt 1): 741–747.
   Google Scholar
• Liou TG, Adler FR, FitzSimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001; 153(4): 345–352.
   PubMed Web of Science ®Google Scholar
• Liou TG, Adler FR, Huang D. Use of lung transplantation survival models to define patient selection in cystic fibrosis. Am J Respir Crit Care Med. 2005; 171 (9): 1053–1059.
   PubMed Web of Science ®Google Scholar
• Sweet SC, Aurora P, Benden C, et al; International Pediatric Lung Transplant Collaborative. Lung transplantation and survivival in children with cystic fibrosis: Solid statistics—flawed interpretation. Pediatr Transplant. 2008; 12(2): 129–136.
   Google Scholar
• LiPuma JJ. Burkholderia cepacia. Management issues and new insights. Clin Chest Med. 1998; 19(3): 473–486.
   Google Scholar
• Smith AL, Redding G, Doershuk C, et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr. 1988; 112(4): 547–554.
   PubMed Web of Science ®Google Scholar
• Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA. 1990; 87(23): 9188–9192.
   PubMed Web of Science ®Google Scholar
• Fuchs HJ, Borowitz DS, Christiansen DH, et al; Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994; 331 (10): 637–642.
   PubMed Web of Science ®Google Scholar
• McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of Dornase alpha in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group. Chest. 1996; 110(4): 889–895.
   PubMed Web of Science ®Google Scholar
• Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic salin e. N Engl J Med. 2006; 354(3): 241–250.
   PubMed Web of Science ®Google Scholar
• Elkins MR, Robinson M, Rose BR, et al; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006; 354(3): 229–240.
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Pepe MS, Quan JM. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999; 340(1): 23–30.
   PubMed Web of Science ®Google Scholar
• LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest. 2001; 120(3 Suppl): 118S–123S.
   PubMed Web of Science ®Google Scholar
• Koyama H, Geddes DM. Erythromycin and diffuse panbronchioliotis. Thorax. 1997; 52(10): 915–918.
   PubMed Web of Science ®Google Scholar
• Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchioloitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998; 157(6 Pt 1): 1829–1832.
   Google Scholar
• Saiman L, Marshall BC, Mayer-Hamblett N, et al; Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with pseudominas aeruginosa: a randomized controlled trial. JAMA. 2003; 290(13): 1749–1756.
   PubMed Web of Science ®Google Scholar
• Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax. 2006; 61(10): 895–902.
   PubMed Web of Science ®Google Scholar
• Tsai WC, Rodriguez ML, Young KS, et al. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med. 2004; 170(12): 1331–1339.
   PubMed Web of Science ®Google Scholar
• Tateda K, Ishii Y, Matsumoto T, et al. Direct evidence for antipseudomonal activity of marcolides: Exposure-dependent bactericidal activity and inhibition of protein synthesis by Erythromycin, Clarithromycin, and Azithromycin. Antimicrob Agents Chemother. 1996; 40(10): 2271–2275.
   PubMedGoogle Scholar
• Liou TG, Adler FR, Cahill BC, et al. Survival effect of lung transplantation among patients with cystic fibrosis. JAMA. 2001; 286(21): 2863–2689.
   Google Scholar
• Hodson ME. Treatment of cystic fibrosis in the adult. Respiration. 2000; 67(6): 595–607.
   Google Scholar
• Dobbin CJ, Bye PT. Adults with cystic fibrosis: meeting the challenge. Int Med J. 2003; 33(I2): 593–597.
   Google Scholar